1. Ovarian cancer survival by tumor dominance, a surrogate for site of origin
- Author
-
Anneli Loo, Harvey A. Risch, Isabel Fan, John R. McLaughlin, Steven A. Narod, Anna Ivanova, Christopher P. Crum, Barry P. Rosen, Joanne Kotsopoulos, and Shelley S. Tworoger
- Subjects
Adult ,Oncology ,endocrine system ,Cancer Research ,medicine.medical_specialty ,endocrine system diseases ,Carcinoma, Ovarian Epithelial ,Article ,Young Adult ,Internal medicine ,medicine ,Carcinoma ,Fallopian Tube Neoplasms ,Humans ,Epithelial ovarian cancer ,Neoplasms, Glandular and Epithelial ,Young adult ,Fallopian Tubes ,Aged ,Dominance (genetics) ,Site of origin ,Ovarian Neoplasms ,Hematology ,business.industry ,Middle Aged ,medicine.disease ,female genital diseases and pregnancy complications ,medicine.anatomical_structure ,Female ,business ,Ovarian cancer ,Fallopian tube - Abstract
Recent studies suggest that a proportion of ovarian tumors may actually originate in the distal fallopian tube. The objective of this study was to examine the relationship between dominance (a surrogate for site of origin) and survival, following a diagnosis of epithelial ovarian cancer.We classified 1,386 tumors as dominant (putatively originating in the ovary) and non-dominant (putatively originating in the fallopian tube), using parameters obtained from pathology reports. Dominant tumors were restricted to one ovary or one involved ovary that exceeded the other in dimension by at least twofold, while non-dominant tumors were identified as having a greater likelihood of a tubal origin if the disease was equally distributed across the ovaries. Cox proportional hazards models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) associated with dominance.Non-dominant tumors were more likely to be serous, stage III/IV, and be associated with a BRCA1/2 mutation, increasing parity and use of estrogen hormone replacement therapy (p ≤ 0.01). In contrast, 46 and 26% of the dominant tumors were serous and endometrioid, respectively, with a more even distribution of stage (p0.0001). Women with a non-dominant tumor had an increased risk of death compared to women with a dominant tumor (multivariate HR 1.28; 95% CI 1.02-1.60). Findings were similar in our analysis restricted to serous only subtypes (HR 1.28; 95% CI 1.01-1.63).These preliminary findings suggest significantly worse survival among women diagnosed with a tumor putatively arising from fallopian tube.
- Published
- 2015
- Full Text
- View/download PDF